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Available online 16 August 2016Signaling pathways play an important role in cardiogenesis. Secreted frizzled-related protein 4 (SFRP4), a mem-
ber of the Wnt family, contributes to adipogenesis and tumorigenesis. However, how SFRP4 participates in
cardiogenesis and the detailed molecular mechanisms involved have not been elucidated. The aim of this work
was to determine cross-talk between SFRP4, integrin α1β1, and Notch1 during cardiac differentiation of
P19CL6 cells. Using a well-established in vitro P19CL6 cell cardiomyocyte differentiation system, we found that
SFRP4 inhibited P19CL6 cell cardiac differentiation via SFRP4 overexpression or knockdown. In addition, the
SFRP4 overexpression augmented Notch1 and HES1 production. Further investigation demonstrated that
SFRP4 bound to integrin α1β1 to activate the focal adhesion kinase (FAK) pathway and that phosphorylated
FAK Y397 (p-FAK Y397) aided Notch intracellular domain 1 (NICD1) nuclear translocation to form a p-FAK
Y397–NICD1 complex that activated the Hes1 promoter. Taken together, the cross-talk between SFRP4, integrin
α1β1, and Notch1 suppresses the cardiac differentiation of P19CL6 cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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In recent years, cell therapy has rapidly advanced as a potential strat-
egy for treating cardiovascular diseases [1]. Remarkable progress has al-
ready been made both in basic research and clinical studies of the roles
stem cells play in the therapy of heart diseases [2]. Embryonic stem cells
(ESCs), bonemarrow stem cells (BMSCs), and induced pluripotent stem
cells (iPSCs) have been used in myocardial repair therapy studies. De-
spite this, the related adverse effects and ethical issues have limited
their clinical applications.
Involved in cardiac differentiation, theWnt, Notch, bonemorphoge-
netic protein (BMP), and ﬁbroblast growth factor (FGF) signaling path-
ways have been investigated extensively for their roles in cardiogenesis
[3]. However, the interplay between these signaling pathways remains
largely unknown.
Wnt signaling regulates a group of evolutionarily conserved path-
ways that play a central role in a diverse set of cellular activities [3].
Wnt/β-catenin signaling is critical for vertebrate cardiac development.
Early activation ofWnt/β-catenin signaling promotes cardiac differenti-
ation, whereas late activation of Wnt/β-catenin signaling inhibits heart
formation [4].y andMolecular Biology, School
iovascular Sciences,Ministry of
China.
nyanzhou@bjmu.edu.cn
. This is an open access article underSecreted frizzled-related proteins (SFRP1–5) are a family of glyco-
proteins that act as antagonists to the Wnt ligands [5]. SFRPs are com-
posed of a netrin-like (NTR) domain and a cysteine-rich domain
(CRD). The CRD shares 70% homology with Wnt receptors and com-
petes for Wnt ligands [5].
Notch signaling pathway was comprised of four transmembrane re-
ceptors (Notch 1–4) and ﬁve transmembrane ligands (Delta-like 1, 3, 4,
and Jagged 1 and 2) that are expressed on the surface of manymamma-
lian cell types [6]. Notch1 signaling initiates cardiomyocyte differentia-
tion by directly regulating Nkx2.5 transcription [7]. Notch4 efﬁciently
determines the cardiac fate of hemangioblasts, resulting in the genera-
tion of populations consisting of 60% cardiomyocytes [8]. The identiﬁca-
tion of mutations in several Notch signaling components, which result
in heart diseases, demonstrates the clear importance of Notch signaling
in cardiogenesis.
Notch andWnt/β-catenin signaling often intersect in stem cells and
progenitor cells, and mutually regulate their transcription. The molecu-
larmechanismof this cross-talk, however, is still obscure. It appears that
cross-talk between Notch andWnt signaling may be involved in differ-
ent biological processes. The expression of Notch intracellular domain 1
(NICD1), the active form of the Notch1 intracellular domain, is depen-
dent on Wnt/β-catenin pathway activation. Moreover, Notch1 nega-
tively contributes to Wnt/β-catenin signaling modulation. Knockdown
of Notch1 with lentivirus Notch1 short hairpin RNA (N1ShRNA)
upregulates the active form of β-catenin [9]. However, the interaction
between SFRPs and the Notch pathway remains unclear. SFRPs interactthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Primers used for quantitative real-time RT-PCR.
Primers Sequence (5′–3′) Product size
18s rRNA F: CTGCTTTTCAGCAACTGGTCA
R: TAGGACTGGCTACCATGCTGT
151 bp
Islet-1 F: CTGCTTTTCAGCAACTGGTCA
R: TAGGACTGGCTACCATGCTGT
123 bp
Gata4 F:CACCCCAATCTCGATATGTTTGA
R: GGTTGATGCCGTTCATCTTGT
151 bp
α-Mhc F: GCCCAGTACCTCCCGAAAGTC
R:CCATCCAATCGGTAGTAGCG
110 bp
β-Mhc F: ACAACCCCTACGATTATGCGT
R: ACGTCAAAGGCAGTATCCGTG
121 bp
Integrin α1 F: TACCGTGTCACCCTTGATTC
R: TCCTGCAAGTCGTGCTTATC
129 bp
Integrin α3 F: GTGACTAATGCTTTCTGCTC
R: TAGGTCTGACGAAAGATGTA
132 bp
Integrin α5 F: TGGTTCGGAGCAACAGTTCG
R: CCAAAATCTGAGCGGCAAGG
120 bp
Integrin α7 F: GGGAGGTGCTGTGTATGTGT
R: AAGACCTTCCCATCTCCGTC
123 bp
Integrin β1 F: ATAGAGAATCCCAGAGCTC
R: GGTAATCTTCAGCCCTCTTG
120 bp
Integrin β3 F: AGAAATCCAAAGAGCAGAAG
R: ATGAGGATGTAGTTCTTGGC
123 bp
SFRP1 F: CCAGCGAGTACGACTACG
R: CCTGCTGCTTCACCTCTG
111 bp
SFRP2 F: CAGCCCGACTTCTCCTAC
R: CTCCAGCACCTCCTTCAT
117 bp
SFRP3 F: TGGTAAACATTCCAAGGGAC
R: GACTTTCTTACCAAGCCGAT
126 bp
SFRP4 F: ACAGCACTCAGGAGAACG
R: AGGAACTCCAGGGTACAG
108 bp
SFRP5 F: GCCTCCAGTGACCAAGAT
R: CAATCAACTTTCGGTCCC
108 bp
Hes-1 (for ChIP) F: TCCTCCCATTGGCTGAA
R: GGCCCTGGCGGCCTCTAT
121 bp
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tors, except for binding with Wnt ligands or Fz receptors [10]. Integrins
are transmembrane receptors that act as bridges for cell–ECM connec-
tions and cell–cell interactions. Integrin receptors are obligate heterodi-
mers composed of two different chains, termed α and β subunits. The
α1, α3, α5, α7, β1, and β3 subunits are mainly expressed in
cardiomyocytes [11]. The initiation of the terminal differentiation of
cells can be partially inhibited by adhesion-blocking antibodies to
integrin β1. Nevertheless, the role of integrin in cardiac differentiation
is unclear [12].
This study ﬁrst reports that SFRP4 inhibits the cardiac differentiation
of P19CL6 cells by binding with integrin α1β1 to accelerate focal adhe-
sion kinase (FAK) Y397 phosphorylation, while the activated FAK pro-
motes NICD1 translocation into the nucleus, and FAK Y397 and NICD1
form a complex to inhibit the expression of cardiac genes. Our study un-
covers the cross-talk of SFRP4, integrin α1β1, and the Notch1 pathway,
which serves to increase our understanding of heart development.
2. Materials and methods
2.1. Cell culture, induction of differentiation, and reagents
P19CL6 cells were cultured as described previously [14]. Brieﬂy, the
cells were grown in a 60-mm tissue culture–grade dish under adherent
conditions with minimal essential medium supplemented with 10%
fetal bovine serum (FBS, HyClone), penicillin (100 U/ml), and strepto-
mycin (100 U/ml) (growth medium), and were maintained in 5% CO2
at 37 °C.
To induce cardiac differentiation under adherent conditions, the
cells were plated at a density of 3.7 × 105 in a 60-mm tissue culture–
grade dish with growth medium containing 1% dimethyl sulfoxide
(DMSO, Sigma-Aldrich) (differentiation medium), which was changed
every other day. The days of differentiation were numbered consecu-
tively after the ﬁrst day of DMSO treatment (day 0).
Recombinant SFRP4 (100 ng/ml; 9115G2, Sigma-Aldrich)was added
to the cell cultures every 2 days.
2.2. Real-time reverse transcription (RT)-PCR
Total RNA extraction from P19CL6 cells and real-time RT-PCR were
performed as previously described [13]. Transcript levels were normal-
ized to 18S rRNA levels. The primers are listed in Table 1. Each value rep-
resents the average of at least three independent experiments.
2.3. Plasmid transfection and RNA interference
P19CL6 cellswere transfectedwith plasmids or synthesized small in-
terfering RNA (siRNA) for gene overexpression or knockdown, respec-
tively. The plasmid carrying NICD1 (pCDNA3.1-NICD1) was a kind gift
fromDr.Martin Baron (University ofManchester). The plasmid carrying
FAKwas a kind gift from Dr. Weiguo Zhu (Peking University Health Sci-
ence Center). The SFRP4 plasmid was a kind gift from Dr. Arattner
(Johns Hopkins University). Plasmid and siRNA transfection was per-
formed using Lipofectamine 2000 and Lipofectamine RNAiMAX
(Invitrogen), respectively, according to the manufacturer's protocols.
After 48-hour transfection, the cells were harvested for functional as-
says. All experiments were performed at least three times.
2.4. Western blotting
Western blotting was performed as previously described [14]. The
antibodies used were against SFRP4 (9115G2, Sigma-Aldrich), integrin
α1 (sc-271034, Santa Cruz), integrin (ITG) β1 (EP1041y, Abcam), FAK
(3286, CST), phosphorylated (p)-FAK Y397 (sc-11765-R, Santa Cruz),
ISLET1 (09218-2E7, Abnova), GATA4 (sc-25310, Santa Cruz), lamin B
(sc-6217, Santa Cruz), glyceraldehyde-3-phosphate dehydrogenase(GAPDH; ab-9484, Abcam), NICD1 (ab8925, Abcam), and HES1 (sc-
13844, Santa Cruz).
2.5. Immunoﬂuorescence staining
Immunoﬂuorescence staining was performed as previously de-
scribed [15]. Nuclei were counterstained with Hoechst 33342 (Sigma-
Aldrich). A minimum of ﬁve randomly imaged ﬁelds from each cover-
slip were counted from at least ﬁve coverslips. P19CL6 cells were incu-
bated with antibodies against p-FAK Y397 (1:200; sc-11765-R, Santa
Cruz) and against NICD1 (1:100; ab8925, Abcam) and subsequently in-
cubated with tetramethylrhodamine isothiocyanate (TRITC)-conjugat-
ed goat anti-rabbit immunoglobulin G (IgG, 1:200; Santa Cruz) or
ﬂuorescein isothiocyanate (FITC)-conjugated rabbit anti-goat IgG
(1:200; Santa Cruz) for 30 min at room temperature. Immunoﬂuores-
cence staining was visualized under an Olympus FV1000 confocal
laser scanning microscope (Tokyo, Japan).
2.6. Luciferase assay
The luciferase (Luc) assay was performed as previously described
[15]. The plasmid carrying the HES1-Luc reporter gene was a kind gift
from Prof. Diane S. Krause (University of Yale). The pGL-Basic plasmid
was co-transfected as the internal control. Luciferase activity was mea-
sured and normalized to Renilla luciferase activity. All experimentswere
performed in triplicate.
2.7. Coimmunoprecipitation (CoIP) assay
CoIP was performed according to the manufacturer's instructions
(Roche). P19CL6 cell lysates were incubated with antibodies against
1808 Y. Tian et al. / Cellular Signalling 28 (2016) 1806–1815ITGα1 (sc-271034, Santa Cruz) and ITGβ1 (EP1041y, Abcam) or normal
IgG for 2 hwith gentle rotation, and thenwith 50 μl protein G Sepharose
slurry (Roche) at 4 °C for 1 h. Immunoprecipitates were washed three
times with wash buffer, subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE), and then detected
with anti-SFRP4 antibody.
2.8. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed according to a previously described method
[14]. The antibodies used for immunoprecipitation were anti–p-FAK
Y397 (sc-11765-R, Santa Cruz) and anti-NICD1 (sc-28713, Santa Cruz)
antibodies. The primers used for the Hes1 promoter were 5′-TCCTCC
CATTGGCTGAAA-3′ (forward) and 5′-GGCCCTGGCGGCCTCTAT-3′ (re-
verse). The target product length was 101 bp.2.9. Statistical analysis
The data are reported as themean± standard deviation (SD). Com-
parisons between groups were analyzed by one-way analysis of vari-
ance (ANOVA). Signiﬁcance was analyzed with SPSS 10.0 software and
P b 0.05 was considered statistically signiﬁcant.3. Results
3.1. SFRP4 expression is stage-speciﬁc during P19CL6 cell cardiac
differentiation
After 1% DMSO treatment, P19CL6 cells underwent cardiac differen-
tiation as indicated by the upregulation of ISLET1, GATA4, α–myosin
heavy chain (α-MHC), and β-MHC. These results conﬁrmed that
P19CL6 cells successfully differentiated into cardiomyocytes (Fig. 1A
and B).Fig. 1. The expression proﬁles of cardiac-speciﬁc genes and SFRP family members during P19CL
Gata4,α-Mhc, and β-MHC expression in DMSO-induced P19CL6 cells. (C) Real-time RT-PCR exa
blotting examination of the SFRP4 expression proﬁle. Real-time RT-PCR data are from three ind
three samples (*P b 0.05, **P b 0.01 vs. 0 days). Western blotting images are representative ofNext, we examined the SFRP family expression proﬁle (Fig. 1C).
SFRP2, SFRP3, and SFPR5 were nearly undetectable; SFRP1 was
expressed throughout the differentiation. Interestingly, SFRP4 expres-
sion showed a stage-speciﬁc pattern (Fig. 1C and D). SFRP4 was upreg-
ulated earlier and peaked at day 6, indicating that it may participate in
the cardiac differentiation of P19CL6 cells.
3.2. SFRP4 inhibits cardiac gene expression in P19CL6 cells
The expression of cardiac genes was decreased in cultures to which
100 ng/ml SFRP4 recombinant proteins had been added during induc-
tion as compared to the control (Fig. 2A and B), demonstrating the
role of SFRP4 in P19CL6 cell differentiation. At the same time,
transfecting 100 nM Sfrp4-speciﬁc siRNA (si-Sfrp4) enhanced the ex-
pression of the genes (Fig. 2C and D). These results indicate that SFRP4
inhibits the expression of cardiac genes during P19CL6 cell
differentiation.
3.3. SFRP4 overexpression upregulates Notch1 and HES1
We showed that SFRP4 inhibits the cardiac differentiation of P19CL6
cells. However, the detailed mechanism of SFRP4 remains unclear. Wnt
and Notch1 can co-function to regulate cardiac differentiation; conse-
quently, we attempted to determine whether SFRP4, a member of the
Wnt family, can regulate cardiac differentiation via cross-talk between
the Wnt and Notch1 pathways.
We examined the expression proﬁles of Wnt and Notch pathway
molecules (Fig. S1). Wnt3a was expressed at day 3, while that of
AXIN2 and β-catenin were expressed after day 4. Notch1 expression in-
creased at day 2, and then declined. HES1 increased and peaked at day 6,
and then decreased, which was similar to SFRP4 expression.
Next, we assessed the effects of SFRP4 on cross-talk between the
Wnt and Notch1 signaling pathways. As shown in Fig. 3A and B, com-
pared to the vector control at day 12 following DMSO induction,6 cell cardiac differentiation. (A, B) Real-time RT-PCR and western blot detection of Islet1,
mination of SFRP family member (Sfrp1, Sfrp2, Sfrp3, Sfrp4, Sfrp5) expression. (D)Western
ependent experiments, each performed in triplicate. Bars represent the mean ± SD from
three independent experiments; GAPDH was used as the internal control.
Fig. 3. SFRP4 overexpression upregulates the Notch1 signaling pathway. (A, B) Real-time RT-PCR andwestern blot detection ofWnt3a, β-catenin, Notch1, and HES1 expression in P19CL6 cells
after SFRP4 treatment (OE, SFRP4 construct transfection). Cells treatedwith pcDNA3.1were used the control (Empty). (C, D) Real-timeRT-PCR andwestern blot detection ofWnt3a,β-catenin,
Notch1, and HES1 expression in P19CL6 cells treated with si-Sfrp4. Cells treated with non-silencing RNA were used as the control. Real-time RT-PCR data are from three independent
experiments, each performed in triplicate. Bars represent the mean ± SD from three samples (*P b 0.05 vs. control of the same day). Western blotting images are representative of three
independent experiments; GAPDH was used as the internal control.
Fig. 2. SFRP4 inhibits the expression of cardiac-speciﬁc genes during P19CL6 cell cardiac differentiation. (A, B) Real-time RT-PCR and western blotting analysis of Islet1, Gata4,α-Mhc, and β-
Mhc expression in P19CL6 cells treatedwith recombinant SFRP4 protein (100 ng/ml) duringDMSO induction (OE, SFRP4 overexpression). Cellswithout SFRP4 recombinant proteins (Empty)
wereused as the control. (C, D) Real-time RT-PCRandwestern blot analysis of ISLET1, GATA4,α-MHC, andβ-MHCexpression in P19CL6 cells transfectedwith si-Sfrp4. Cells treatedwith non-
silencing RNA were used as the control. Real-time RT-PCR data are from three independent experiments, each performed in triplicate. Bars represent the mean ± SD from three samples
(*P b 0.05, **P b 0.01 vs. control of the same day). Western blotting images are representative of three independent experiments; GAPDHwas used as the internal control.
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Fig. 4. The SFRP4–Notch1 signaling pathway inhibits P19CL6 cell cardiac differentiation. (A) Real-time RT-PCR detection of Islet1, Gata4, α-Mhc, and β-Mhc expression in P19CL6 cells
treated with Notch1. Cells treated with pcDNA3.1 were used as the control. (B) Real-time RT-PCR detection of Islet1, Gata4, α-Mhc, and β-Mhc expression in DAPT-treated P19CL6 cells.
Cells untreated with DAPT were used as the control. (C) Real-time RT-PCR analysis of ISLET1, GATA4, α-MHC, and β-MHC expression in P19CL6 cells treated with pcDNA3.1, SFRP4,
DAPT, SFRP4 + DAPT, si-Sfrp4, Notch1, or si-SFRP4+ Notch1. 18S rRNA served as the internal control. Data are the mean ± SD (n = 3). *P b 0.05, **P b 0.01 vs. 0 days; aP b 0.05 vs.
pcDNA-3.1; bP b 0.05 vs. P19CL6 (6 days); cP b 0.05 vs. SFRP4; dP b 0.05 vs. DAPT; eP b 0.05 vs. Notch1; fP b 0.05 vs. si-Sfrp4. Western blotting images are representative of three
independent experiments; GAPDH was used as the internal control.
Fig. 5. ITGα1β1 inhibits P19CL6 cell cardiac differentiation. (A, B) Real-time RT-PCR and western blotting detection of ISLET1, GATA4, α-MHC, β-MHC, and TNNI3 expression in P19CL6
cells treated with ITGβ1 (OE, ITGβ1 overexpression). Cells treated with pcDNA3.1 were used as the control (Empty). (C, D) Real-time RT-PCR and western blotting detection of ISLET1,
GATA4, α-MHC, β-MHC, and TNNI3 expression in P19CL6 cells treated with ITGβ1 siRNA. Cells treated with non-silencing RNA were used as the control. Real-time RT-PCR data are
from three independent experiments, each performed in triplicate. Bars represent the mean ± SD from three samples (*P b 0.05, **P b 0.01 vs. control of the same day). Western
blotting images are representative of three independent experiments; GAPDH was used as the internal control.
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Fig. 6. SFRP4 interacts with ITGα1β1. (A, top) Real-time RT-PCR detection of ITGα1 and
ITGβ1 expression in P19CL6 cells treated with SFRP4. Cells treated with pcDNA 3.1 were
used as the control. (A, bottom) Real-time RT-PCR detection of ITGα1 and ITGβ1
expression in P19CL6 cells treated with si-Sfrp4. Cells treated with non-silencing RNA were
used as the control. (B) CoIP detection of the ITGα1β1–SFRP4 complex in the membrane of
P19CL6 cells. Real-time RT-PCR data are from three independent experiments, each
performed in triplicate. Bars represent mean ± SD from three samples (*P b 0.05 vs.
control of the same day). Western blotting images are representative of three independent
experiments.
1811Y. Tian et al. / Cellular Signalling 28 (2016) 1806–1815SFRP4 overexpression decreasedWnt3a, β-catenin, and AXIN2 (Fig. S2)
expression, but enhanced Notch1 and HES1 expression. At the same
time, transfection with 100 nM si-Sfrp4 increased Wnt3a and β-
catenin production, but decreased Notch1 and HES1 levels (Fig. 3C
and D, Fig. S2). Therefore, we investigated the effects of the Notch1 sig-
naling pathway on cardiac differentiation. Real-time RT-PCR demon-
strated that cardiac genes were downregulated when P19CL6 cells
were transfected with Notch1 (Fig. 4A). We also treated P19CL6 cells
with the Notch1 signaling pathway inhibitor DAPT (100 ng/ml) for
12 days. Notch1 knockdown increased cardiac gene expression
(Fig. 4B). These results are indicative of the effect of Notch1 inhibition
on P19CL6 cell cardiac differentiation.
Rescue assay was performed to examine the effect of SFRP4 and
Notch1 signalingmolecule cross-talk on of P19CL6 cell cardiac differen-
tiation (Fig. 4C). The expression levels of the cardiac-speciﬁc genes
Islet1, Gata4,α-Mhc, and β-Mhcwere rescued by SFRP4 overexpression,
DAPT, si-SFRP4, Notch1, or combinations thereof. These results indicate
that SFRP4 and Notch signaling might interact to inﬂuence cardiomyo-
cyte differentiation. Accordingly, we used CoIP to examine the possible
interactions between them. However, there was no direct interaction
between SFRP4 and Notch1 (data not shown).
3.4. SFRP4–ITGα1β1 activates FAK phosphorylation and inhibits cardiac
differentiation
The SFRP4 CRD interacts with othermembrane receptors in addition
to Wnt ligands or receptors. SFRP1 inhibited ITGα3β1 in MDA-MB-231
breast carcinoma cells [16]. We hold the view that SFRP4 interacts with
integrin receptors during P19CL6 cell differentiation.
We detected the expression proﬁle of integrin molecules present in
the cardiomyocytes (Fig. S3). The similar expression patterns of ITGα1,
ITGβ1, and SFRP4 indicated that the molecules are correlated.
To clarify the effect of ITGα1β1 on cardiac differentiation, we
transfected pcDNA3.1-Integrin β1 or ITGβ1 siRNA (si-integrin β1) into
P19CL6 cells. Islet1, Gata4, α-Mhc, β-Mhc, and troponin I (Tnni3) levels
were decreased after ITGβ1 overexpression (Fig. 5A and C); while
ITGβ1 knockdown increased these markers (Fig. 5B and D), suggesting
that ITGα1β1 inﬂuences P19CL6 cell cardiac differentiation.
To explore the correlation of SFRP4 and ITGα1β1, we overexpressed
or knocked down SFRP4 in P19CL6 cells. SFRP4 promoted the expres-
sion of ITGβ1 and ITGα1 (Fig. 6A).
We performed a CoIP assay to test the interaction between SFRP4
and ITGα1β1. SFRP4 interacted with ITGα1β1 on the plasma mem-
brane, which indicated that ITGα1β1 could be a new interaction path-
way with SFRP4 (Fig. 6B).
We established that activation of the integrin signaling pathway led
to FAK Y397 autophosphorylation. FAK Y397 expression was enhanced
at day 6 compared to that on day 0 (Fig. 7A). SFRP4 overexpression
promoted FAK Y397 expression as compared to the controls (Fig. 7B).
Conversely, SFRP4 knockdown decreased p-FAK Y397 levels (Fig. 7C).
These results indicate that SFRP4 promotes FAK Y397 phosphorylation.
The co-functioning of SFRP4 and ITGα1β1 on P19CL6 cell cardiac
differentiation was explored in a rescue assay. The expression of Islet1
and other cardiac genes was restored by SFRP4 overexpression and
FAK inhibitor or si-Sfrp4 and FAK (Fig. 7D).
Collectively, these results indicate that SFRP4 and ITGα1β1 can form
a complex to inhibit P19CL6 cell cardiac differentiation through the
activated FAK pathway. ITGα1β1 signaling may serve as a non–Wnt-
dependent pathway that interacts with SFRP4.
3.5. Nuclear FAK and NICD1 form a complex and inhibit P19CL6 cell cardiac
differentiation
We proved that SFRP4 can combine with ITGα1β1 and activate the
ITGα1β1–FAK signaling pathway. However, the interaction between
SFRP4 and the Notch1 pathway remains unknown.Weexamined the co-function of SFRP4 and FAK onNotch1 andHES1
expression. Notch1 and HES1 productionwas rescued by SFRP4 overex-
pression and FAK inhibitor, or si-Sfrp4 and FAK, respectively. The results
provide an indication that SFRP4 and FAK co-function to promote
Notch1 and HES1 expression (Fig. 8A). FAK overexpression enhanced
NICD1 nuclear translocation (Fig. 8B).
The immunoﬂuorescence assay demonstrated thatNICD1 andp-FAK
Y397 colocalize in the nuclei (Fig. 8C); CoIP showed that p-FAK Y397
and NICD exist a complex (Fig. 8D).
Phosphorylated FAK Y397 could act as a transcriptional regulator;
herein, HES1–Luc activity was increased most signiﬁcantly following
FAK and NICD1 plasmid transfection (Fig. 9A). ChIP showed that
NICD1 and FAK were recruited to the Hes1 promoter region (Fig. 9B).
Accordingly, FAK and NICD1 are present in a complex to activate HES1
transcription effectively.
FAK and NICD1 co-function in P19CL6 cell cardiac differentiationwas
investigated using rescue assay (Fig. 9C). The expression levels of the car-
diac genes Islet1, Gata4, α-Mhc, and β-Mhc were rescued by DAPT and
FAK overexpression or FAK inhibitor and Notch1 overexpression. These
data demonstrate that the FAK–NICD1 complex decreases the expression
levels of these cardiac genes by recruitment to the promoter of Hes1, the
downstream gene of Notch1, to activate its transcriptional activity.
4. Discussion
Heart diseases remain a major worldwide healthcare burden.
Recent advances in stem cell biology have made it feasible to replace
Fig. 7. SFRP4 activates the ITGα1β1 signaling pathway. (A)Western blot analysis of p-FAKY397 and FAK expression on day 0 and day 6 in P19CL6 cells. (B)Western blot detection of p-FAK
Y397 and FAK expression in P19CL6 cells with SFRP4 overexpression (OE). Cells treated with pcDNA 3.1 (Empty) were used as the control. (C)Western blot detection of p-FAK Y397 and
FAK expression in P19CL6 cells treated with si-SFRP4. Cells treated with non-silencing RNA were used as the negative control (NC). (D) Real-time RT-PCR analysis of Islet1, Gata4, α-Mhc,
and β-Mhc expression following treatment with SFRP4, FAK inhibitor, si-Sfrp4, FAK, SFRP4+ FAK inhibitor, or si-Sfrp4+ FAK. Cells treated with pcDNA 3.1 were used as the control. 18S
rRNA served as the internal control. The data are from three independent experiments. Bars represent the mean ± SD from three samples (*P b 0.05, **P b 0.01 vs. 0 days; aP b 0.05 vs.
pcDNA-3.1; bP b 0.05 vs. P19CL6 (6 days); cP b 0.05 vs. SFRP4; dP b 0.05 vs. FAK inhibitor; fP b 0.05, eP b 0.05 vs. FAK vs. si-Sfrp4). Western blotting images are representative of three
independent experiments.
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cardiomyocyte differentiation remain unclear, which restrict the ob-
tainment of myocytes from stem cells.
In the present study, we explored the effect of SFRP4 on cardiac dif-
ferentiation. SFRP4 accelerates adipogenic differentiation in human ad-
ipose tissue–derived mesenchymal stem cells [18], and it can sensitize
glioma stem cells (GSCs) to chemotherapeutics [19]. However, there
has been no report on SFRP4 in cardiac differentiation. We ﬁrstdetermined that SFRP4 can inhibit cardiac differentiation in P19CL6
cells. It is notable that SFRP1 is expressed throughout P19CL6 cell differ-
entiation into cardiomyocytes. SFRP1 is strongly induced in differentiat-
ing heartmuscle and is required for the formation of normal-sized heart
muscle in the embryo [20]. In addition, the loss of SFRP1 leads to abnor-
mal cardiac function in the form of aberrant expression of Wnt ligands
(Wnt1, 3, 7b, and 16) and Wnt target genes (Wisp1 and Lef1) in aged
hearts [16].
Fig. 8. ITGα1β1 promotes the Notch1 signaling pathway. (A) Real-time RT-PCR detection of Notch1 and HES1 expression in P19CL6 cells treated with SFRP4, FAK inhibitor, si-Sfrp4, FAK,
SFRP4+FAK inhibitor, or si-Sfrp4+FAK. Cells treatedwith pcDNA3.1were used as the control. (B)Western blot detection of FAK andNICD1 expression in P19CL6 cells on day 0 and day 6
after FAK construct transfection (OE) or pcDNA3.1 transfection (Empty). The data are from three independent experiments. Bars represent themean± SD from three samples (*P b 0.05,
vs. pGL-Basic; aP b 0.05 vs. pcDNA-3.1; bP b 0.05 vs. P19CL6 (6 days); cP ≤ 0.05 vs. SFRP4; dP ≤ 0.05 vs. FAK inhibitor; eP ≤ 0.05 vs. FAK; fP ≤ 0.05 vs. si-Sfrp4). (C) NICD1 and FAK Y397
expression in P19CL6 cells at day 0 and day 6 was analyzed by immunoﬂuorescence staining with monoclonal antibody against NICD1 (green) and p-FAK Y397 (red). Nuclei were
counterstained with Hoechst 33342 (blue). (D) CoIP was performed in P19CL6 cells to detect the NICD–FAK Y397 complex in the nuclear and cytoplasmic proteins.
1813Y. Tian et al. / Cellular Signalling 28 (2016) 1806–1815SFRP family members are generally considered Wnt antagonists.
They compete for Wnt ligands because they share the same CRD with
theWnt receptor. The SFRP4 CRD also can interact with other receptors,
which indicates that SFRP4 may play its role through a non–Wnt-
dependent signaling pathway [5]. We found that SFRP4 interacted
with ITGα1β1. However, SFRP4 may also bind to other integrin mole-
cules, which requires further conﬁrmation. There are three main path-
ways downstream of the integrin pathway, namely the integrin-linked
kinase (ILK), FAK, and SRC pathways, of which the FAK pathway is a
major pathway. FAK Y397 is autophosphorylatedwhen the integrin sig-
naling pathway is activated. During human ESC (hESC) differentiation,
ITGα6 levels diminish and FAK Y397 is phosphorylated and activated
[21]. Administration of SFRP1 recombinant protein to the testis in vivo
delayed spermiation, which was accompanied by the downregulation
of p-FAK Tyr397 [22]. In our study, upregulated SFRP4 leaded to p-FAK
Y397 upregulation, implying that SFRP4 can activate the ITGα1β1–
FAK signaling pathway.
FAK is a non-receptor tyrosine kinase bearing a central kinase do-
main ﬂanked by an N-terminal band 4.1, ezrin, radixin, moesin homol-
ogy (FERM) domain and a C-terminal region containing a focal
adhesion targeting (FAT) domain and several proline-rich motifs [23].We demonstrated that FAK can interact with NICD1 to activate the pro-
moter activities of target genes. The Notch signaling pathway plays a
critical role during mammalian cardiac development. Gain- and loss-
of-function experiments for Notch signaling components have shown
that this pathway is a crucial regulator of cardiomyocyte differentiation
in ESCs [9]. Notch1 inactivation favors ESC differentiation into
cardiomyocytes, whereas endogenous Notch signaling promotes ESC
differentiation into the neuronal lineage [8]. Our data reveal that
Notch1 inhibits the cardiomyocyte differentiation of P19CL6 cells by
interacting with FAK and NICD1.5. Conclusions
Our results provide evidence for cross-talk between SFRP4,
ITGα1β1, and Notch1 for inhibiting P19CL6 cell cardiac differentiation.
SFRP4 binds with ITGα1β1 to activate the FAK pathway. FAK Y397 is
autophosphorylated and enters the nucleus, where it interacts with
NICD1 to promote the transcriptional activities of the target cardiac
genes to decrease their expression. Consequently, SFRP4 inhibits cardiac
differentiation via cross-talk of the ITGα1β1 and Notch1 pathways.
Fig. 9. FAK and NICD1 forma complex to inhibit P19CL6 cell cardiac differentiation. (A) HES1 luciferase activity wasmeasured at day 6 after transfectionwith FAK, NICD1, or FAK+NICD1.
Cells treated with pGL-Basic were used as the control. (B) ChIP analysis of the NICD1–FAK Y397 complex recruited to the HES1 promoter. Soluble chromatin was prepared from P19CL6
cells at day 6 followed by immunoprecipitation with antibodies against NICD1 or FAK Y397. The extracted DNA was ampliﬁed by real-time RT-PCR using primers that covered the NICD-
binding sites on the Hes1 enhancer region. (C) Real-time RT-PCR analysis of P19CL6 cells treated with FAK, DAPT, FAK inhibitor, Notch1, FAK + DAPT, or Notch1 + FAK inhibitor. Cells
treated with pcDNA3.1 were used as the control. The data are from three independent experiments. Bars represent the mean ± SD from three samples (*P b 0.05, vs. pGL-Basic;
aP b 0.05 vs. pcDNA-3.1; bP b 0.05 vs. P19CL6 (6 days); cP b 0.05 vs. FAK; dP b 0.05 vs. DAPT; eP b 0.05 vs. Notch1; fP b 0.05 vs. FAK inhibitor).
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